Advertisement

Topics

Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study

12:12 EDT 16 Apr 2019 | Investing News Network

Algernon Pharmaceuticals Inc. (CSE:AGN) (FRANKFURT:AGW) (OTCB:BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that after additional biochemical analysis, NP-135, one of its lead compounds for non-alcoholic steatohepatitis (“NASH”), showed that in addition to being metabolically neutral in a number of important measurements, it further demonstrated a 34.6% reduction of a key secondary marker of fibrosis, liver hydroxyproline.

The post Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study appeared first on Investing News Network.

Original Article: Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study

NEXT ARTICLE

More From BioPortfolio on "Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...